ReviewCardiovascular diabetology2020

Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk.

Francesco Giorgino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.